Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II R-COMP in cardiopathic patients with diffuse large B-cell lymphoma
2009-012143-42Phase 2Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Aug 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, doxorubicin, cyclophosphamide, vincristine and prednisone in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), sponsored by Fondazione Italiana Linfomi. Primary endpoints: Response rate at 1 year and Progression-free survival at 1 year. Started Aug 2009; status: completed.
02
Drugs
rituximabdoxorubicincyclophosphamidevincristineprednisone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on 2009-012143-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012143-42.